Sep 05, 2020

Role of EZH1 in EZH2-deficient hematopoiesis

Contributor Leukemia

Behind the paper

Role of EZH1 in EZH2-deficient hematopoiesis

Kazumasa Aoyama

Aug 29, 2020

RUNX1 Mutations in the Context of Personalized Approach in Blast Phase Chronic Myeloid Leukemia

Contributor Leukemia

Behind the paper

RUNX1 Mutations in the Context of Personalized Approach in Blast Phase Chronic Myeloid Leukemia

+2

Shady Adnan-Awad and 2 others

Aug 25, 2020

Contributor Leukemia

Behind the paper

Ibrutinib plus chemoimmunotherapy demonstrates preliminary efficacy in children with relapsed/refractory mature B-NHL

Amos Burke

Aug 21, 2020

Contributor Leukemia

Behind the paper

Significant association of cutaneous adverse events with hydroxyurea

Frank Stegelmann

Aug 14, 2020

Behind the Paper: MDM2 inhibition in cancer therapy

Contributor Leukemia

Behind the paper

Behind the Paper: MDM2 inhibition in cancer therapy

Marina

Aug 11, 2020

The Nub of the Oncotherapy Problem..and resistance to decitabine or 5-azacytidine

Contributor Leukemia

Behind the paper

The Nub of the Oncotherapy Problem..and resistance to decitabine or 5-azacytidine

Yogen

Aug 11, 2020

Contributor Leukemia

Behind the paper

International Harmonization of MRD in Myeloma

Advances in multiple myeloma (MM) therapies have enhanced the likelihood of achieving deeper treatment responses which in turn carry significant prognostic implications.

+2

Luciano J Costa and 2 others

Aug 11, 2020

Contributor Leukemia

Behind the paper

RNA editing as diversifier of genetic information in Leukemia

Implications of RNA editing on chronic lymphocytic leukemia

Roland Geisberger

Aug 07, 2020

Behind-the-paper: Whole-genome Sequencing Identifies Responders to Pembrolizumab in Relapse/Refractory Natural-killer/T Cell Lymphoma

Contributor Leukemia

Behind the paper

Behind-the-paper: Whole-genome Sequencing Identifies Responders to Pembrolizumab in Relapse/Refractory Natural-killer/T Cell Lymphoma

+3

Jing Quan Lim and 3 others

Aug 05, 2020

Contributor Leukemia

Behind the paper

Defining the role of salvage transplant in crowded therapeutic space in relapsed myeloma

Binod Dhakal

Aug 04, 2020

Dasatinib as a therapy for AML

Contributor Leukemia

Behind the paper

Dasatinib as a therapy for AML

Disha Malani

Jul 25, 2020

Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency

Contributor Leukemia

Behind the paper

Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency

Emilia

Jul 24, 2020

Infection susceptibility predates CLL

Contributor Leukemia

Behind the paper

Infection susceptibility predates CLL

Michael Asger Andersen

Jul 21, 2020

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Contributor Leukemia

Behind the paper

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Mirle Schemionek

Jul 21, 2020

Contributor Leukemia

Behind the paper

Development of mRNA-generated CD8+ CAR T: Toward more accessible CAR-T therapy in multiple myeloma treatment

YU-TZU TAI

Jul 16, 2020

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

Contributor Leukemia

Behind the paper

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

Elisa Laurenti

Jul 15, 2020

Contributor Leukemia

Behind the paper

Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia

Lev Kats

Jul 13, 2020

Contributor Leukemia

Behind the paper

Therapy-related Myelodysplastic Syndromes deserve specific diagnostic sub-classification and risk-stratification

Andrea Kuendgen

Jul 10, 2020

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia

Contributor Leukemia

Behind the paper

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia

Arnold Kloos

Jul 09, 2020

Nature Research Cancer Community

Leukemia

The long non-coding RNA CRNDE regulates IL6 signalling in multiple myeloma

Role of EZH1 in EZH2-deficient hematopoiesis

RUNX1 Mutations in the Context of Personalized Approach in Blast Phase Chronic Myeloid Leukemia

Ibrutinib plus chemoimmunotherapy demonstrates preliminary efficacy in children with relapsed/refractory mature B-NHL

Significant association of cutaneous adverse events with hydroxyurea

Behind the Paper: MDM2 inhibition in cancer therapy

The Nub of the Oncotherapy Problem..and resistance to decitabine or 5-azacytidine

International Harmonization of MRD in Myeloma

RNA editing as diversifier of genetic information in Leukemia

Behind-the-paper: Whole-genome Sequencing Identifies Responders to Pembrolizumab in Relapse/Refractory Natural-killer/T Cell Lymphoma

Defining the role of salvage transplant in crowded therapeutic space in relapsed myeloma

Dasatinib as a therapy for AML

Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency

Infection susceptibility predates CLL

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Development of mRNA-generated CD8+ CAR T: Toward more accessible CAR-T therapy in multiple myeloma treatment

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia

Therapy-related Myelodysplastic Syndromes deserve specific diagnostic sub-classification and risk-stratification

Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia

Register to Nature Research Cancer Community